Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases
- PDF / 521,131 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 110 Downloads / 184 Views
GYNECOLOGIC ONCOLOGY: ORIGINAL ARTICLE
Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases Douglas V. N. P. Oliveira 1 & Kira P. Prahm 1 & Ib J. Christensen 1 & Anker Hansen 2 & Claus K. Høgdall 3 & Estrid V. Høgdall 1 Received: 5 June 2020 / Accepted: 21 October 2020 # The Author(s) 2020
Abstract Ovarian cancer (OC) is the second most frequent type of gynecological cancers worldwide. In the past decades, the development of novel diagnostic and prognostic biomarkers available for OC has been limited, reflecting by the lack of specificity of such markers or very costly management. Microarray expression profiling has shown very effective results in exploring new molecular markers for patients with OC. Nonetheless, most screenings are focused on mutations or expression of molecules that are translated into proteins, corresponding to only 2% of the total human genome. In order to account for the vast majority of transcripts, in the present exploratory study, we assessed the expression levels of a comprehensive panel of noncoding RNA in different subtypes of OC. We further evaluated their association with patient overall survival (OS) and aggressive forms of the disease, such as tumor type, stage, and chemotherapy resistance. By microarray profiling in a total of 197 epithelial OC patients (162 serous carcinomas, 15 endometrioid carcinomas, 11 mucinous carcinomas, and 9 clear cell carcinomas), we found two candidates, SNORA68 and SNORD74, which associated with OS and poor clinicopathological features. The overexpression of those two targets combined was correlated with shorter OS and progression-free survival. That association was further observed to correlate with a more aggressive form of the disease. Overall, the results indicate that a panel comprised of SNORA68 and SNORD74 may be clinically relevant, where patients could be offered a more individualized, targeted follow-up, given its further validation on future prospective clinical studies. Keywords ncRNA profiling . Biomarker . Ovarian cancer . High throughput
Introduction Globally, ovarian cancer (OC) is the eighth most common cancer for women and the second most common cause of gynecologicassociated cancer death [1, 2]. Within the past 25 years, all cancer collectively have presented an improvement in overall survival (OS) rate by 27% in developed countries, with an
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s43032-02000372-7. * Estrid V. Høgdall [email protected] 1
Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
2
Oncology Venture, Hoersholm, Denmark
3
Department of Gynecology, Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
exception of OC [2, 3]. Survival rate increment for OC has been marginal worldwide, with a 5-year survival remaining at approximately 41–47%, and with an estimate of approximately 293,000 new cases and 185,000 associated deaths annuall
Data Loading...
